JP2001507669A - サイクリン依存キナーゼ結合性化合物 - Google Patents
サイクリン依存キナーゼ結合性化合物Info
- Publication number
- JP2001507669A JP2001507669A JP51249897A JP51249897A JP2001507669A JP 2001507669 A JP2001507669 A JP 2001507669A JP 51249897 A JP51249897 A JP 51249897A JP 51249897 A JP51249897 A JP 51249897A JP 2001507669 A JP2001507669 A JP 2001507669A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- protein
- substance
- amino acid
- cyclin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.サイクリン依存キナーゼ(cdk)に結合する特性を有する物質であ って、 (i)全長p16タンパク質のアミノ酸残基84から103、あるいは、その活性部分 または誘導体を含むペプチド、または、 (ii)そのフラグメント、活性部分または誘導体の機能的類似物を含有し、全長p1 6、p15、p18及びp19タンパク質以外である物質。 2.サイクリン依存タンパク質が、cdk4またはcdk6である請求項1記載 の物質。 3.物質のサイクリン依存タンパク質への結合が、pRbリン酸化の阻害 を生ずる請求項1または2記載の物質。 4.ペプチドが、全長p16タンパク質のアミノ酸残基89から97を含 む請求項1から3のいずれかに記載の物質。 5.ペプチドフラグメントが、全長p16タンパク質のアミノ酸残基90 から92に相当するアミノ酸モチーフFLD、及び/または、全長p16タンパク質の アミノ酸残基94から97に相当するLVVLを含む請求項1から4のいずれかに記 載の物質。 6.ペプチドフラグメントが、FLDxLVVLのアミノ酸モチーフを含み、x が1又はそれ以上のアミノ酸を表す請求項5記載の物質。 7.ペプチドフラグメントのアスパラギン酸残基が、全長p16タンパク 質の92位に相当する位置において、疎水性アミノ酸残基に置換された請求項1 から6のいずれかに記載の物質。 8.疎水性アミノ酸残基がアラニンである請求項8記載の物質。 9.p16、p15、p18またはP19タンパク質から誘導された請求項1から8 のいずれかに記載の物質。 10.キャリア分子に結合し、当該物質が細胞に輸送され得るようにさ れた請求項1から9のいずれかに記載の物質。 11.キャリア分子が、アンテナペディアホメオドメインから誘導され たペプチドを含む請求項10記載の物質。 12.ペプチドフラグメントが安定化分子に結合した請求項1から11 のいずれかに記載の物質。 13.請求項1から12のいずれかに記載の物質の1またはそれ以上を 、生理学的に許容されるキャリアとともに含有してなる製薬組成物。 14.医療的処置に用いるための請求項1から12のいずれかに記載の 物質。 15.過剰増殖疾患の処置用医薬の調製における、請求項1から12に いずれかに記載の物質の使用。 16.過剰増殖疾患が、癌、乾癖または動脈発生である請求項15記載 の使用。 17.請求項1から12のいずれかに記載の物質をコードする核酸。 18.発現調節配列を結合した請求項17記載の核酸を取り込んだベク ター。 19.請求項1から12のいずれかに記載の物質の、(i)前記物質の生 物学的活性の1又はそれ以上を有する化合物、または、(ii)前記物質の結合パー トナーである化合物をスクリーニングする方法における使用。 20.請求項1から12のいずれかに記載の物質と競合する化合物を同 定する方法であって、 (a)予め設定した量の検出可能なラベルをした物質をサイクリン依存キ ナーゼ(cdk)に結合させ、 (b)候補となる化合物を添加し、そして、 (c)cdkに結合したままのラベル化合物の量、あるいは、候補となる化合 物で置換されたラベル化合物の量を測定することを含んでなる方法。 21.請求項1から12のいずれかに記載の物質の類似物を同定する方 法であって、 (a)1またはそれ以上の候補となる化合物を固体基質上に固定化し、 (b)該基質をラベル化サイクリン依存キナーゼ(cdk)に曝し、 (c)cdkに結合した候補化合物を選択することを含んでなる方法。 22.cdkが、網状赤血球溶解物中で生成される請求項20または21 記載の方法。 23.サイクリン依存キナーゼが、cdk4またはcdk6である請求項20か ら22のいずれかに記載の方法。 24.候補化合物のpRbリン酸化の阻害特性について試験すること、及 び/または該化合物の細胞がS相へ入ることを阻害する特性について試験するこ とを更に含む請求項20から23のいずれかに記載の方法。 25.候補化合物が、合成結合ライブラリから選択される請求項20か ら24のいずれかに記載の方法。 26.全長p16タンパク質のアミノ酸残基90から92に相当するアミ ノ酸モチーフFLD、及び/または、全長p16タンパク質のアミノ酸残基94から9 7に相当するLVVLを含むp16タンパク質のフラグメントの、前記アミノ酸モチー フの三次元構造に類似するようにモデル化された有機化合物の設計における使用 であって、当該有機化合物が、サイクリン依存タンパク質に結合する、及び/ま たはpRbリン酸化を阻害する特性を有する使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9519275.3 | 1995-09-21 | ||
GBGB9519275.3A GB9519275D0 (en) | 1995-09-21 | 1995-09-21 | Substances and their therapeutic use |
PCT/GB1996/002340 WO1997011174A1 (en) | 1995-09-21 | 1996-09-23 | Cyclin depenpent kinase binding compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001507669A true JP2001507669A (ja) | 2001-06-12 |
JP2001507669A5 JP2001507669A5 (ja) | 2004-09-30 |
JP4077514B2 JP4077514B2 (ja) | 2008-04-16 |
Family
ID=10781044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51249897A Expired - Fee Related JP4077514B2 (ja) | 1995-09-21 | 1996-09-23 | サイクリン依存キナーゼ結合性化合物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6569833B1 (ja) |
EP (1) | EP0851922B1 (ja) |
JP (1) | JP4077514B2 (ja) |
KR (1) | KR19990045761A (ja) |
AT (1) | ATE188254T1 (ja) |
AU (1) | AU6996796A (ja) |
DE (1) | DE69605934T2 (ja) |
ES (1) | ES2143780T3 (ja) |
GB (1) | GB9519275D0 (ja) |
WO (1) | WO1997011174A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010266460A (ja) * | 2002-08-01 | 2010-11-25 | Mtm Laboratories Ag | 溶液ベースの診断のための方法 |
JP2014510135A (ja) * | 2011-04-06 | 2014-04-24 | オブスヘストボ エス オグラニクヘンノイ オトベトストベンノスト’ウ ”メタマク” | 高増殖性疾患治療のための医薬組成物 |
JP2018517137A (ja) * | 2015-05-22 | 2018-06-28 | エクスプレッション、パソロジー、インコーポレイテッドExpression Pathology, Inc. | サイクリン依存性キナーゼ阻害剤2A(p16)タンパク質のためのSRM/MRMアッセイ |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9519275D0 (en) | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
US6495526B2 (en) | 1996-01-23 | 2002-12-17 | Gpc Biotech, Inc. | Inhibitors of cell-cycle progression and uses related thereto |
US6489305B1 (en) | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
KR19990086091A (ko) * | 1998-05-25 | 1999-12-15 | 성재갑 | 곤충세포를 이용한 가용성 cdk4/p16 복합체의 대량발현 방법 |
KR20000019888A (ko) * | 1998-09-16 | 2000-04-15 | 성재갑 | 곤충세포를 이용한 cdk4/hc△p16 복합체의 제조방법 및이로부터 cdk4 단백질의 정제방법 |
KR20000019889A (ko) * | 1998-09-16 | 2000-04-15 | 성재갑 | 곤충세포를 이용한 cdk4/p16 복합체의 제조방법 |
US6644696B2 (en) | 1998-10-23 | 2003-11-11 | Coinstar, Inc. | Coin-discriminator voucher anti-counterfeiting method and apparatus |
US7166475B2 (en) * | 1999-02-26 | 2007-01-23 | Cyclacel Ltd. | Compositions and methods for monitoring the modification state of a pair of polypeptides |
WO2001011367A1 (fr) * | 1999-08-04 | 2001-02-15 | Medical & Biological Laboratories Co., Ltd. | Methode d'analyse de l'activite enzymatique de phosphorylation du complexe cycline/cdk |
GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
GB0030378D0 (en) | 2000-12-13 | 2001-01-24 | Cyclacel Ltd | Compound |
CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
CN101507822B (zh) | 2003-11-24 | 2012-06-06 | 坎吉有限公司 | 皮肤瘢痕形成的减少 |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
US7858813B2 (en) | 2004-08-19 | 2010-12-28 | Dsm Ip Assets B.V. | Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products |
EP1799230B1 (en) | 2004-08-27 | 2012-11-21 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
GB0419416D0 (en) * | 2004-09-01 | 2004-10-06 | Inst Of Ex Botany Ascr | 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof |
RU2456297C1 (ru) * | 2010-11-19 | 2012-07-20 | Федеральное государственное учреждение "Российский научный центр рентгенрадиологии" Министерства здравоохранения и социального развития России | Химерный пептид для лечения фиброаденомы молочной железы |
EA028151B1 (ru) | 2013-04-03 | 2017-10-31 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "МетаМакс" (ООО "МетаМакс") | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |
WO2024036044A1 (en) * | 2022-08-08 | 2024-02-15 | The Johns Hopkins University | Compositions and methods for treating and preventing metabolic disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362623A (en) | 1991-06-14 | 1994-11-08 | The John Hopkins University | Sequence specific DNA binding by p53 |
FR2662698A1 (fr) * | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
CA2086829A1 (en) | 1990-07-09 | 1992-01-10 | Sayeeda Zain | Diagnosis of metastatic cancer by the mts-1 gene |
NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
JPH07509251A (ja) | 1992-07-22 | 1995-10-12 | ザ トラスティーズ オブ プリンストン ユニバーシティ | p53ワクチン |
US6211334B1 (en) | 1992-10-16 | 2001-04-03 | Cold Spring Harbor | Cell-cycle regulatory proteins, and uses related thereto |
DE69333043T2 (de) * | 1992-10-16 | 2004-05-06 | Cold Spring Harbor Laboratory | Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen |
US5700657A (en) | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
EP0702730A4 (en) | 1994-03-18 | 1997-05-07 | Univ Utah Res Found | COREWAY MUTTATIONS IN THE MTS GENE AND METHODS FOR DETECTING AN APPROXIMATION OF CANCER IN THE MTS GENE |
US5631156A (en) * | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
HUP9901908A3 (en) | 1995-07-17 | 2000-02-28 | Univ Texas | P16 expression constructs and their application in cancer therapy |
GB9519275D0 (en) | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
US5669833A (en) * | 1996-08-21 | 1997-09-23 | Stone; David B. | Soccer training system |
-
1995
- 1995-09-21 GB GBGB9519275.3A patent/GB9519275D0/en active Pending
-
1996
- 1996-09-23 AU AU69967/96A patent/AU6996796A/en not_active Abandoned
- 1996-09-23 EP EP96931174A patent/EP0851922B1/en not_active Expired - Lifetime
- 1996-09-23 ES ES96931174T patent/ES2143780T3/es not_active Expired - Lifetime
- 1996-09-23 JP JP51249897A patent/JP4077514B2/ja not_active Expired - Fee Related
- 1996-09-23 DE DE69605934T patent/DE69605934T2/de not_active Expired - Fee Related
- 1996-09-23 WO PCT/GB1996/002340 patent/WO1997011174A1/en not_active Application Discontinuation
- 1996-09-23 KR KR1019980702005A patent/KR19990045761A/ko not_active Application Discontinuation
- 1996-09-23 AT AT96931174T patent/ATE188254T1/de not_active IP Right Cessation
- 1996-09-23 US US09/043,560 patent/US6569833B1/en not_active Expired - Fee Related
-
2002
- 2002-11-01 US US10/286,964 patent/US20040029791A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010266460A (ja) * | 2002-08-01 | 2010-11-25 | Mtm Laboratories Ag | 溶液ベースの診断のための方法 |
JP2013210373A (ja) * | 2002-08-01 | 2013-10-10 | Roche Mtm Laboratories Ag | 溶液ベースの診断のための方法 |
JP2014510135A (ja) * | 2011-04-06 | 2014-04-24 | オブスヘストボ エス オグラニクヘンノイ オトベトストベンノスト’ウ ”メタマク” | 高増殖性疾患治療のための医薬組成物 |
JP2018517137A (ja) * | 2015-05-22 | 2018-06-28 | エクスプレッション、パソロジー、インコーポレイテッドExpression Pathology, Inc. | サイクリン依存性キナーゼ阻害剤2A(p16)タンパク質のためのSRM/MRMアッセイ |
Also Published As
Publication number | Publication date |
---|---|
EP0851922B1 (en) | 1999-12-29 |
ES2143780T3 (es) | 2000-05-16 |
US6569833B1 (en) | 2003-05-27 |
DE69605934T2 (de) | 2000-06-15 |
JP4077514B2 (ja) | 2008-04-16 |
US20040029791A1 (en) | 2004-02-12 |
AU6996796A (en) | 1997-04-09 |
KR19990045761A (ko) | 1999-06-25 |
ATE188254T1 (de) | 2000-01-15 |
GB9519275D0 (en) | 1995-11-22 |
DE69605934D1 (de) | 2000-02-03 |
EP0851922A1 (en) | 1998-07-08 |
WO1997011174A1 (en) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001507669A (ja) | サイクリン依存キナーゼ結合性化合物 | |
Slebos et al. | p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. | |
Elledge et al. | A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis | |
US20080249025A1 (en) | Methods and Means For Inhibition of CDK4 Activity | |
Rodriguez et al. | Functional characterization of human nucleosome assembly protein-2 (NAP1L4) suggests a role as a histone chaperone | |
JPH10506525A (ja) | MDM2とp53タンパク質との結合阻害並びにその治療応用 | |
WO1994029727A1 (en) | Inhibiting protein interactions | |
JP3633616B2 (ja) | 転写因子dp−1 | |
JP2001517439A (ja) | 53bp2複合体 | |
WO1997014794A1 (en) | ACTIVATION OF p53 PROTEIN | |
KR100565819B1 (ko) | 신호 전달 단백질과 glgf(pdz/dhr)도메인간의 상호작용을 저해하는 조성물과 상기 조성물의 용도 | |
JPH10509312A (ja) | p21▲上WAF1▼−PCNA相互作用部位の同定とその治療における応用 | |
KR19990008407A (ko) | 피시엔에이 결합물질 | |
WO2002008282A2 (en) | Bstp-ras/rerg protein and related reagents and methods of use thereof | |
EP0792359B1 (en) | Transcription factor e2f-4 | |
US7067646B2 (en) | Methods and compositions for modulating tumor suppression | |
WO1999050280A1 (en) | Compositions and methods for controlling brca1-mediated p53-dependent and -independent regulation of transcription | |
US6673902B2 (en) | Cyclin D binding factor, and uses thereof | |
US8173604B2 (en) | Inhibition of Skp2-cyclin a interaction | |
JP2002503466A (ja) | 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質 | |
JP2002516394A (ja) | E2f活性を調節するためのアッセイ、方法及び手段 | |
Cohen | The Sonic Hedgehog Signaling Pathway | |
Vikis | Signaling mechanisms of the semaphorin receptor plexin-B1 | |
Mandati | The role of the C-terminus Merlin in its tumor suppressor function | |
Lovisa | Role of p27kip1 in cancer progression: new insight into its post-translational regulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080108 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080201 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110208 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |